Business
Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights
Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R Announced positive Phase 3 SOL-1 results in February 2026, first ever successful wet AMD superiority trial comparing a novel investigative agent to an approved anti-VEGF SOL-1 Week 52 data presentations held at Macula Society and VBS meetings reinforce AXPAXLI’s unmatched durability and sustained disease control data in wet AMD Commercial preparedness plans accelerated a
About this update from Ocular Therapeutix, Inc.
[{"type":"image","alt":"Ocular Therapeutix, Inc.","displaySize":"","headline":null,"caption":"Ocular Therapeutix, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/67aba0a08455988daf68787482afba8f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/x8AZ3pCd8rX_NNStYxPmTQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MQ--/https://media.zenfs.com/en/globenewswire.com/67aba0a08455988daf68787482afba8f","width":300,"height":101}},"lazy":false},{"type":"text","content":"Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R","length":126,"tagName":"p"},{"type":"text","content":"Announced positive Phase 3 SOL-1 results in February 2026, first ever successful wet AMD superiority trial comparing a novel investigative agent to an approved anti-VEGF","length":169,"tagName":"p"},{"type":"text","content":"SOL-1 Week 52 data presentations held at Macula Society and VBS meetings reinforce AXPAXLI’s unmatched durability and sustained disease control data in wet AMD","length":159,"tagName":"p"},{"type":"text","content":"Commercial preparedness plans accelerated as Ocular intends to submit AXPAXLI NDA based on SOL-1 Week 52 data, subject to ongoing formal discussions with the U.S. FDA","length":166,"tagName":"p"},{"type":"text","content":"SOL-R Phase 3 non-inferiority trial in wet AMD on track for topline readout in 1Q 2027","length":86,"tagName":"p"},{"type":"text","content":"HELIOS-3 Phase 3 trial in diabetic retinopathy ongoing","length":54,"tagName":"p"},{"type":"text","content":"Ocular to host Investor Day on Wednesday, June 17, 2026, in New York City, including key program and regulatory updates","length":119,"tagName":"p"},{"type":"text","content":"Cash balance of $666.7 million as of March 31, 2026, with expected runway into 2028 ","length":83,"tagName":"p"},{"type":"text","content":"BEDFORD, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights.","length":304,"tagName":"p"},{"type":"text","content":"“2026 is off to a tremendous start for Ocular, driven by the superiori...